Clinical Trial Update: Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase III clinical trial update for GR1802 injection targeting atopic dermatitis; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• GR1802 (GR1802)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Atopic Dermatitis | Phase 3 | Status: UNKNOWN